Tesamorelin

Body Composition & Fat Loss

Tesamorelin is an FDA-approved GHRH analogue that specifically targets visceral fat reduction while enhancing lean body mass, metabolic health, and overall body composition through natural growth hormone stimulation.

Key Benefits

Visceral fat reduction • Lean mass enhancement • Metabolic improvement • Body composition • Quality of life

Standard Protocol

2 mg daily subcutaneous injection in lower abdomen. Rotate sites. Evening administration preferred.

Minimum Order: 5 Units

SKU:N/D Categoría:Peptidos

Descripción

Growth Hormone & Body Composition

Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH) that has gained FDA approval for treating HIV-associated lipodystrophy. This innovative peptide specifically targets visceral adipose tissue (VAT) reduction while offering comprehensive benefits for body composition, metabolic health, and overall well-being. Tesamorelin represents a clinical-grade solution for those seeking targeted fat reduction and metabolic optimization.

Clinical Benefits

Visceral Fat Reduction: Clinically proven to reduce visceral adipose tissue (VAT), leading to significant decreases in abdominal fat accumulation
Metabolic Health Improvement: Enhances insulin sensitivity and glucose metabolism, supporting overall metabolic function and diabetes prevention
Lean Body Mass Enhancement: Promotes the development and maintenance of lean muscle tissue while preserving existing muscle mass
Quality of Life Enhancement: Users report significant improvements in self-esteem, body image, and overall confidence related to body composition changes
Cardiovascular Benefits: Reduction in visceral fat correlates with improved cardiovascular health markers and reduced disease risk
Growth Hormone Optimization: Naturally stimulates growth hormone release without suppressing endogenous production

Professional Dosage Protocol

For optimal results and safety, Tesamorelin should be administered according to established clinical guidelines:

2 mg

Once Daily Subcutaneous Injection

This standardized dosage has been extensively studied in clinical trials and represents the optimal balance between efficacy and safety for most individuals.

Administration Guidelines

Injection Site: Administer in the lower abdomen, carefully avoiding the navel area and any existing scar tissue
Site Rotation Protocol: Systematically rotate injection sites to minimize local irritation, tissue hardening, and injection site reactions
Skin Preparation: Ensure injection sites are completely free of scars, bumps, bruises, or any skin conditions that may impair absorption
Timing Consistency: Administer at the same time each day, preferably in the evening, to maintain consistent blood levels
Storage Requirements: Store reconstituted product refrigerated and follow proper peptide storage protocols
Sterile Technique: Always use proper sterile injection techniques and dispose of needles safely